C3 GLOMERULOPATHY
Clinical trials for C3 GLOMERULOPATHY explained in plain language.
Never miss a new study
Get alerted when new C3 GLOMERULOPATHY trials appear
Sign up with your email to follow new studies for C3 GLOMERULOPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug under watch: korean study tracks Real-World safety
Disease control Not yet recruitingThis study aims to monitor the safety and effectiveness of the drug Iptacopan (Fabhalta®) in real-world medical settings in Korea. It will follow about 21 adult patients who have been diagnosed with either Paroxysmal Nocturnal Hemoglobinuria (PNH, a rare blood disease) or C3 Glom…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
First Real-World look at new kidney disease pill
Knowledge-focused Not yet recruitingThis study will observe 83 adults with a rare kidney disease called C3 glomerulopathy (C3G) who are already taking the approved drug iptacopan. Researchers will review patients' medical records from before and after starting the medication to understand who gets treated and how t…
Matched conditions: C3 GLOMERULOPATHY
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC